Lunai Bioworks (LNAI) Risk Analysis
Risk Overview Q2, 2026
Source: the company's latest filing for the period ended Jun 30, 2026, filed Oct 13, 2026
Risk Change Over Time
- Share Price & Shareholder Rights - Risk 1We may be unable to maintain compliance with the continued listing requirements of The Nasdaq Capital Market, and our Common Stock could be delisted.
Our Common Stock is listed on The Nasdaq Capital Market, which imposes continued listing requirements, including a minimum bid price of $1.00 per share, minimum stockholders' equity or market value requirements, and corporate governance standards. We have previously received deficiency notices from Nasdaq, and we effected reverse stock splits of our Common Stock in September 2025 and May 2026 in part to regain and maintain compliance with the minimum bid price requirement. We are currently subject to a one-year Mandatory Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(B), and if we again fail to satisfy the Bid Price Rule during the monitoring period, the Listing Qualifications Department will issue a delist determination rather than a new compliance period. As of June 30, 2026, we had a stockholders' deficit of $9,024,946, which is below the $2,500,000 minimum stockholders' equity requirement of Nasdaq Listing Rule 5550(b)(1). If Nasdaq determines that we do not satisfy that requirement or one of the alternative continued listing standards under Nasdaq Listing Rule 5550(b), we could receive a deficiency notice or a delisting determination. There can be no assurance that we will maintain compliance with the applicable continued listing requirements. If our Common Stock were delisted, the liquidity and market price of our Common Stock would likely be materially adversely affected, our ability to raise capital would be impaired, and our Common Stock could become subject to the "penny stock" rules, which could further limit trading in our Common Stock.
- Share Price & Shareholder Rights - Risk 2The conversion of our Series B Convertible Preferred Stock would result in substantial dilution to our existing stockholders, and the Series B Preferred Stock ranks senior to our Common Stock upon liquidation.
In connection with the Neurobridge acquisition, we issued eight shares of Series B Convertible Preferred Stock with an aggregate stated value of $20.0 million. The Series B Preferred Stock is not convertible unless and until the Company obtains the stockholder approval required under Nasdaq Listing Rules 5635(a) and 5635(d) in connection with the Neurobridge acquisition and the potential issuance upon conversion of shares representing 20% or more of the Company's pre-transaction outstanding Common Stock. Following receipt of such approval, the Series B Preferred Stock will be convertible into up to 1,666,666 shares of Common Stock at a conversion price of $12.00 per share - reflecting the proportionate adjustment of the original $1.50 conversion price and 13,333,333-share maximum required by the Series B Certificate of Designation for the May 2026 Reverse Stock Split - subject to a 4.99% beneficial ownership limitation (increasable to 9.99% upon 61 days' notice). Based on 4,615,503 shares of Common Stock outstanding as of June 30, 2026, full conversion would represent an increase of approximately 36% in our outstanding shares and would substantially dilute the ownership and voting power of our existing stockholders, and sales of the shares issued upon conversion (or the perception that such sales may occur) could depress the market price of our Common Stock. In addition, the Series B Preferred Stock has a liquidation preference equal to its aggregate stated value and ranks senior to our Common Stock with respect to distributions upon liquidation, dissolution or winding up. The aggregate liquidation preference of the Series B Preferred Stock is $20.0 million, which substantially exceeds the $1.84 million at which the Series B Preferred Stock is recorded in our consolidated financial statements. The recorded amount reflects the estimated fair value of the Series B Preferred Stock at issuance for accounting purposes and does not limit the amount payable to the holders in a liquidation. In any liquidation, dissolution or winding up of the Company, holders of Series B Preferred Stock would be entitled to receive the full $20.0 million preference before any distribution to holders of our Common Stock and, because our total stockholders' deficit was $9,024,946 at June 30, 2026, holders of Common Stock would likely receive nothing. If the required stockholder approval is not obtained, the Series B Preferred Stock will remain outstanding with such preference. There can be no assurance as to whether or when stockholder approval will be obtained.
- Accounting & Financial Operations - Risk 3We have identified a material weakness in our internal control over financial reporting. If we fail to remediate the material weakness, or otherwise fail to maintain effective internal control over financial reporting, our ability to report our financial results accurately and timely could be adversely affected.
As described in Part II, Item 9A of this Annual Report, management concluded that our disclosure controls and procedures and our internal control over financial reporting were not effective as of June 30, 2026, due to a material weakness attributable to the Company not having adequate resources to address complex accounting matters. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Until remediated, this material weakness could result in errors in our financial statements, cause us to fail to meet our reporting obligations on a timely basis, and lead to a loss of investor confidence and a decline in the market price of our Common Stock. Remediation will require financial and personnel resources that we may not have, and there can be no assurance that our remediation efforts will be successful or that we will be able to maintain effective internal control over financial reporting in the future.
Risk Highlights Q2, 2026
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 58
- Innovation / R&D - Risk 1Our business plan may lead to the initiation of one or more product development programs, the discontinuation of one or more development programs, or the execution of one or more transactions that investors do not agree with or that investors do not perceive as favorable to their investment in our Common Stock.
We are pursuing a strategy to, dependent upon raising sufficient funding to do so, leverage our clinical experience and expertise for the clinical development and regulatory approval of our gene therapy product candidates and advance our AI-driven healthcare technology both for the identification of novel therapeutics, and for the characterization of chemical threat agents and associated countermeasures. As part of our ongoing business strategy, we continue to explore potential opportunities to acquire or license new product candidates and to collaborate on our existing products in development. We cannot be certain that our product candidates will be successfully developed, or that the early clinical trial results of our therapeutic product candidates will be predictive of future clinical trial results. During 2022, we decided to abandon our pan-coronavirus and influenza pipelines as the results did not support further development. We again may determine at any time that one or more of our in-licensed product candidates is not suitable for continued development due to cost, feasibility of obtaining regulatory approvals or any other reason, and may terminate the related license. Our business plan requires us to be successful in a number of challenging, uncertain and risky activities, including pursuing development of our gene therapy product candidates in indications for which we have limited or no human clinical data, designing and executing a nonclinical and/or clinical development program for our product candidates, building internal or outsourced gene therapy capabilities, converting early stage gene therapy research efforts into clinical development opportunities, prioritizing small molecule therapeutics based on their initial efficacy in the zebrafish model, identifying additional promising new assets for development that are available for acquisition or in-license and that fit our strategic focus and identifying potential partners to collaborate on our products. We may not be successful at one or more of the activities required for us to execute this business plan. In addition, we may consider other strategic alternatives, such as mergers, acquisitions, divestitures, joint ventures, partnerships and collaborations. We cannot be sure when or if any type of transaction will result. Even if we pursue a transaction, such transaction may not be consistent with our stockholders' expectations or may not ultimately be favorable for our stockholders, either in the shorter or longer term. Our growth prospects and the future value of our Company are primarily dependent on the progress of our ongoing and planned development programs for our product candidates as well as the outcome of our ongoing business development efforts and pipeline progression, together with the amount of our remaining available cash. The development of our product candidates and the outcome of our ongoing business development efforts and pipeline are highly uncertain. We expect to continue to reassess and make changes to our existing development programs and pipeline strategy. Our plans for our development programs may be affected by the results of competitors' clinical trials of product candidates addressing our current target indications, and our business development efforts and pipeline progression may also be affected by the results of competitors' ongoing research and development efforts. We may modify, expand or terminate some or all our development programs, clinical trials or collaborative research programs at any time as a result of new competitive information or as the result of changes to our product pipeline or business development strategy. We are also actively pursuing non-dilutive funding and contractual opportunities with U.S. and Canadian government agencies in support of our therapeutic programs and biodefense applications. Government funding and procurement priorities may change as a result of budgetary constraints, changes in administration, policy priorities, geopolitical developments or other factors outside our control, which could delay, reduce or eliminate potential funding or contracting opportunities. In addition, our participation in government-funded or defense-related programs could expose us to reputational or investor-perception risks, including differing views regarding government policies, defense activities or the use of technologies developed through such programs. Any such developments could adversely affect our ability to obtain funding, enter into partnerships or maintain support among certain investors or other stakeholders.
- Innovation / R&D - Risk 2We have limited experience in drug development and may not be able to successfully develop any drugs, which would cause us to cease operations.
We have never successfully developed a new drug and brought it to market. Our management and clinical teams have experience in drug development, but they may not be able to successfully develop any drugs. Our ability to achieve revenues and profitability in our business will depend on, among other things, our ability to develop products internally or to obtain rights to them from others on favorable terms; complete laboratory testing and human studies; obtain and maintain necessary intellectual property rights to our products; successfully complete regulatory review to obtain requisite governmental agency approvals; enter into arrangements with third parties to manufacture our products on our behalf; and enter into arrangements with third parties to provide sales and marketing functions. If we are unable to achieve these objectives, we will be forced to cease operations.
- Innovation / R&D - Risk 3Clinical trials are expensive, time-consuming, difficult to design and implement, and involve an uncertain outcome.
Our therapeutic product candidates are still in development and will require extensive clinical testing before we are prepared to submit an application for marketing approval to regulatory authorities. We cannot predict with any certainty if or when we might submit any such application for regulatory approval of our product candidates or whether any such application will be approved by the applicable regulatory authority in our target markets. Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. For instance, regulatory authorities may not agree with our proposed endpoints for any clinical trials of our product candidates, which may delay the commencement of our clinical trials. The clinical trial process is also time-consuming. We estimate that clinical trials of our product candidates will take at least several years to complete. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials, and in the regulatory approval process. In addition, the design of a clinical trial, such as endpoints, inclusion and exclusion criteria, statistical analysis plans, data access protocols and trial sizing, can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be harmed, and our ability to generate revenues may be delayed. In addition, any delays in our clinical trials could increase our costs, cause a drop in our stock price, slow down the approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition, and results of operations.
- Innovation / R&D - Risk 4Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.
We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, the effectiveness of our patient recruitment efforts, delays in enrollment due to travel or quarantine policies, the existing body of safety and efficacy data with respect to the study candidate, the perceived risks and benefits of gene therapy approaches for the treatment of certain diseases, the number and nature of competing existing treatments for our target indications, the number and nature of ongoing trials for other product candidates in development for our target indications, perceived risk of the delivery procedure, patients with pre-existing conditions that preclude their participation in any trial, the proximity of patients to clinical sites and the eligibility criteria for the study. Furthermore, the results we have reported in clinical trials to date and any other results we may report in clinical trials of any of our gene therapy product candidates in the future may make it difficult or impossible to recruit and retain patients in other clinical trials of those gene therapy product candidates. Similarly, negative results reported by our competitors about their product candidates may negatively affect patient recruitment in our clinical trials. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our gene therapy product candidates or could render further development impossible. In addition, we expect to rely on clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to control their actual performance.
- Innovation / R&D - Risk 5ChangedBioSymetrics may be unable to develop and commercialize new products.
BioSymetrics continues to expand its research and development efforts to use their proprietary AI platform to develop new products, including in disease areas beyond cancer and neurology. The commercialization of any new products will require the completion of certain clinical development activities, regulatory activities and the expenditure of additional cash resources. BioSymetrics cannot assure you that it can successfully complete the clinical development of any such products. BioSymetrics also cannot assure you that they will be able to reduce their expenditures sufficiently, generate sufficient revenue from products that they successfully commercialize or otherwise mitigate the risks associated with their business to raise enough capital to develop and commercialize new products. In addition, once BioSymetrics' development efforts for a product are completed, commercialization efforts, including potentially the allocation of resources necessary to comply with applicable laws and regulations, will require significant expenditures. Any failure by BioSymetrics to develop and commercialize new products could have a material adverse effect on their ability to implement their strategy and grow their business.
- Innovation / R&D - Risk 6ChangedIf BioSymetrics' products, or the products of its competitors, directly or indirectly result in harm or injury to patients, BioSymetrics could be subject to significant reputational and liability risks, and its operating results, reputation and business could suffer.
BioSymetrics' success will depend on the market's confidence that their developed products can provide reliable, high-quality results, once such products are launched. BioSymetrics believes that patients, physicians and regulators are likely to be particularly sensitive to errors in the use of their products or failure of their products to perform as described, and there can be no guarantee that their products will meet expectations.
- Innovation / R&D - Risk 7ChangedLunai Bioworks is a pre-clinical biotechnology company and may never be able to successfully develop marketable products or generate any material product revenue. We have a very limited relevant operating history upon which an evaluation of our performance and prospects can be made. There is no assurance that our future operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease operations.
Lunai Bioworks is an early-stage biotechnology company and has not generated any revenue from product sales to date (during fiscal 2026, the Company recognized $51,992 of service revenue). All of our product candidates are in the discovery stage or pre-clinical development stage. Moreover, we cannot be certain that our research and development efforts will be successful or, if successful, that our potential treatments will ever be approved for sale to generate commercial revenues. Our therapeutic pipeline includes cell, gene and immunotherapy involving genetically modified cells targeted to treat cancer, and we rely on third parties under contract in the development of product candidates in our pipeline. There is no guarantee that we will be able to manage and fund the development of a pipeline with multiple target conditions, nor that third parties will meet their obligations to us in connection with our research and development. We and certain third parties, on which we rely, have no relevant operating history upon which an evaluation of our performance and prospects can be made. We are subject to all of the business risks associated with a new enterprise, including, but not limited to, risks of unforeseen capital requirements, failure of treatments either in non-clinical testing or in clinical trials, failure to establish business relationships, failure of our third parties to meet their obligations to us and competitive disadvantages against larger and more established companies. If we fail to become profitable, we may suspend or cease operations.
- Innovation / R&D - Risk 8The results of pre-clinical studies or earlier clinical studies are not necessarily predictive of future results, and if we fail to demonstrate efficacy in our pre-clinical studies and/or clinical trials in the future our future business prospects, financial condition and operating results will be materially adversely affected.
The success of our therapeutic research and development efforts will depend upon our ability to demonstrate the efficacy of the treatments in our pipeline in pre-clinical studies, as well as in clinical trials following IND approval by the FDA. Pre-clinical studies involve testing potential product candidates in appropriate non-human disease models to demonstrate efficacy and safety. Success in pre-clinical studies does not ensure that later clinical studies will generate adequate data to demonstrate the efficacy and safety of an investigational drug. Currently, several of our product candidates, including RENB-DC-11, our genetically-modified allogeneic dendritic therapeutic vaccination platform for solid tumors, and BioS_831, our small molecule compound being developed for epilepsy, are in various stages of pre-clinical development with ongoing and planned pre-clinical studies in conjunction with research institutions and third parties. Despite preliminary data we believe is positive, this does not guarantee that any of these products will proceed to the clinical stage or to approval for commercial use. A number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience than us, have suffered significant setbacks in clinical studies, even after seeing promising results in earlier preclinical or clinical studies. Regulatory agencies evaluate non-clinical data carefully before they will approve clinical testing in humans. If certain non-clinical data reveals potential safety issues or the results are inconsistent with an expectation of the potential product candidates' efficacy in humans, the regulatory agencies may require additional more rigorous testing before allowing human clinical trials. This additional testing will increase program expenses and extend timelines. We may decide to suspend further testing on our potential products or abandon the product lines altogether if, in the judgment of our management and advisors, the pre-clinical test results do not support further development, as we did with our pan-coronavirus and influenza product lines.
- Innovation / R&D - Risk 9ChangedIssues in the development and use of AI, including machine learning and computer vision, in BioSymetrics' AI platform may result in reputational harm or liability.
AI is integrated into BioSymetrics' platform and is a significant element of its business offering going forward. As with many developing technologies, AI presents risks, challenges and unintended consequences that could affect its further development, adoption, and use, and therefore BioSymetrics' business. AI algorithms and training methodologies may be flawed. Data sets may be insufficient, of poor quality, or contain biased information. Inappropriate or controversial data practices by data scientists, engineers, and end-users of BioSymetrics' systems could impair the acceptance of AI solutions. If the analyses that AI applications assist in producing are deficient or inaccurate, BioSymetrics could be subjected to competitive harm, potential legal liability, and brand or reputational harm. Some uses of AI present ethical issues, and BioSymetrics' judgment as to the ethical concerns may not be perceived as accurate. While BioSymetrics aims to develop and use AI responsibly and attempt to identify and mitigate ethical and legal issues presented by its use, BioSymetrics may be unsuccessful in identifying or resolving issues before they arise. If BioSymetrics uses AI as part of its platform in a manner that is controversial or perceived as unethical, this may lead to adverse results for BioSymetrics' financial condition and operations or the financial condition and operations of its collaborators or vendors, which may further lead to BioSymetrics experiencing competitive harm, legal liability and brand or reputational harm. In addition, AI-related issues, deficiencies and/or failures could give rise to legal and/or regulatory action, including with respect to proposed legislation regulating AI in jurisdictions such as the European Union and others, and as a result of new applications of existing data protection, privacy, intellectual property, and other laws.
- Innovation / R&D - Risk 10ChangedThe success and growth of BioSymetrics' business depends upon their ability to continuously innovate and develop new products and technologies.
BioSymetrics' solution is a technology-driven platform that relies on innovation to remain competitive. The process of developing new technologies and products is complex, and we have built and seek to further develop our own technology using the latest in AI and machine learning, cloud-based technologies and other tools to differentiate our products and technologies. In addition, our dedication to incorporating technological advancements into our AI platforms requires significant financial and personnel resources and talent. Our development efforts with respect to these initiatives could distract management from current operations and could divert capital and other resources from other growth initiatives important to our business. We operate in an industry experiencing rapid technological change and frequent product introductions. We may not be able to make technological improvements as quickly as demanded by our customers, or we may not be able to accurately predict the demand or growth of its technological investments, which could harm its ability to attract customers and have a material and adverse effect on its business, results of operations, financial condition and future prospects. In addition, we may not be able to effectively implement new technology-driven products and services as quickly as our competitors or be successful in marketing these products and services to potential customers. If we are unable to successfully and timely innovate, we could experience reputational damage and decreased demand for our AI platforms and other products and technologies and our growth, business, results of operations, financial condition and future prospects could be materially and adversely affected.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.